A dynamic close-up visualization of red blood cells and glucose molecules inside a human artery

A Clinical Review of Continuous Glucose Monitoring in the Hospital Setting

Jennifer N Clements, Kennedy Howard, Emory Moss

Approximately 20–34% of hospitalized patients have a diagnosis of diabetes, while many others experience stress hyperglycaemia, both increasing the occurrence of dysglycaemia in the hospital.1 Hyperglycaemia is associated with increased infection rates and higher mortality rates. Conversely, hypoglycaemia can lead to adverse neurological outcomes, prolonged hospital stays, as well as increased mortality.1 In spite of current guidelines […]

touchREVIEWS in Endocrinology. 2025;21(2):1–4:Online ahead of journal publication

Diabetes

IDF Congress 2019, Busan, Korea

Published Online: Feb 4th 2020

The International Diabetes Federation (IDF) Congress 2019 was held in Busan, Korea, from 2 to 6 December 2019. Delegates from over 170 countries came together to shape the future of diabetes.

www.idf.org/congress

The International Diabetes Federation (IDF) Congress 2019 was held in Busan, Korea, from 2 to 6 December 2019. Delegates from over 170 countries came together to shape the future of diabetes. www.idf.org/congress

This Content is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Celebrating 60 years: Standout moments from EASD 2024

After yet another successful congress, who better to reflect on the highlights than the current EASD President, Prof. Chantal Mathieu? In this interview, we explore the packed agenda, discussing everything from the prestigious prize lectures to ground-breaking research. We explore some of the most exciting data presented, including advancements in long-acting insulins, novel technologies and islet transplantation). We also touch on pivotal type 1 diabetes research (T1D), and a crucial call to action for addressing cardiovascular comorbidities in this patient population.

Related Videos in Diabetes

Benefits of finerenone for patients with type 2 diabetes, cardiovascular, kidney and metabolic complications

Pardeep Jhund

The FINE-HEART program aimed to evaluate the safety and efficacy of finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), in key patient populations with type 2 diabetes, chronic kidney disease, and heart failure. By pooling data from three major Phase III trials—FINEARTS-HF, FIDELIO-DKD, and FIGARO-DKD—this comprehensive analysis sought to provide a clearer understanding of finerenone’s effects on cardiovascular mortality, renal outcomes, and hospitalizations for heart failure. The study also focused on subgroups based on diabetes control, offering valuable insights into its potential role in patients with coexisting conditions.

MiniMed 780G safe and effective for children 2-6 years with type 1 diabetes

Tadej Battelino

The latest clinical evidence surrounding the MiniMed 780G system focuses on expanding its access to younger children with type 1 diabetes. The hope is that by extending its use to children aged 2-6 years, its automated insulin delivery could significantly reduce the burden of diabetes management for families.

Developed by Touch

John Doupis: ADA 83rd Scientific Sessions, 2023: Type 2 diabetes highlights

Dr. John Doupis (Director, Iatriko Paleou Falirou Medical Center, Diabetes Division, Athens, Greece; Editor-in-Chief, touchREVIEWS in Endocrinology) provides his top three highlights from the ADA 83rd Scientific Sessions, 2023 in the field of type 2 diabetes. Disclosures: John Doupis has received consultant ...

Developed by Touch

Chantal Mathieu: ADA 83rd Scientific Sessions, 2023: Research highlights

Prof. Chantal Mathieu (Katholieke Universiteit Leuven, Belgium) provides her highlights from the ADA 83rd Scientific Sessions, 2023 including Teplizumab, an anti-CD3 monoclonal antibody, which was the first disease modifying therapy that delays the progression from stage 2 to stage 3 type 1 diabetes and ...

Developed by Touch

Steven Nissen, ADA 2023: Bempedoic acid for cardiovascular disease risk: The CLEAR Outcomes trial

The CLEAR Outcomes trial was a double-blind, randomized, placebo-controlled trial involving patients who were “statin-intolerant” and had, or were at high risk for, cardiovascular disease. The patients were assigned to receive oral bempedoic acid, 180 mg daily, or placebo. Dr. Steven ...

Developed by Touch

Sean Wharton, ADA 2023: Oral nonpeptide GLP-1 receptor agonist orforglipron for obesity

Orforglipron (LY3502970) is a novel oral non-peptide GLP-1 receptor agonist being developed for patients with obesity or overweight, particularly those with type-2 diabetes. Dr. Sean Wharton (Adjunct Professor at McMaster University and Medical Director of the Wharton Medical Clinic) discusses ...

Developed by Touch

Akhtar Hussain, International Diabetes Federation (IDF): Presidential update

The International Diabetes Federation (IDF) is the global voice of the diabetes community. They are a non-profit umbrella organisation of more than 240 national diabetes associations in 161 countries and territories, working together to improve and empower the lives of the 540 million ...

Developed by Touch

Chantal Mathieu: Research highlights from 2022 in diabetes

2022 saw the FDA approval of teplizumab to delay the onset of type 1 diabetes. In addition, there has also been evidence to suggest the effectivness of SGLT2 inhibitors in type 1 diabetes. We were delighted to speak with our editorial board member ...

Developed by Touch

José García-Tirado, DTM 2022: RocketAP in Practice: Results from Pilot and Feasibility Trials

In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) gives an overview of RocketAP and discusses how the RocketAP compares to the USS-Virginia system and also what the next steps in the clinical development of ...

Developed by Touch

José García-Tirado, DTM 2022: Challenges in the development of artificial pancreas systems

An artificial pancreas is a system made of three parts that work together to mimic how a healthy pancreas controls blood glucose in the body. In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) discusses ...

Developed by Touch

Carol Levy, DTM 2022: The use of Control-IQ technology in prior MDI and basal-only insulin users with type 2 diabetes

In this touchENDOCRINOLOGY interview, Prof. Carol Levy (Icahn School of Medicine at Mount Sinai, New York City, NY, USA) discusses her study which evaluated adults with type 2 diabetes using the t:slim X2 insulin pump with Control-IQ technology to show ...

Developed by Touch

Carol Levy, DTM 2022: Benefits of insulin pump in people living with type 2 diabetes

Insulin pumps are electronic devices that help you stabilise your blood glucose levels and control your diabetes. Control-IQ technology could be a powerful management solution for therapy needs of individuals living with type 2 diabetes. In this touchENDOCRINOLOGY interview, Prof. Carol ...

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Already have an Account?

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Learning Activities

Journals

Specialities

A Clinical Review of Continuous Glucose Monitoring in the Hospital Setting

Learning Activities

Journals

Specialities

A Clinical Review of Continuous Glucose Monitoring in the Hospital Setting

IDF Congress 2019, Busan, Korea

This Content is for
Members Only

Celebrating 60 years: Standout moments from EASD 2024

Benefits of finerenone for patients with type 2 diabetes, cardiovascular, kidney and metabolic complications

MiniMed 780G safe and effective for children 2-6 years with type 1 diabetes

John Doupis: ADA 83rd Scientific Sessions, 2023: Type 2 diabetes highlights

Chantal Mathieu: ADA 83rd Scientific Sessions, 2023: Research highlights

Steven Nissen, ADA 2023: Bempedoic acid for cardiovascular disease risk: The CLEAR Outcomes trial

Sean Wharton, ADA 2023: Oral nonpeptide GLP-1 receptor agonist orforglipron for obesity

Akhtar Hussain, International Diabetes Federation (IDF): Presidential update

Chantal Mathieu: Research highlights from 2022 in diabetes

José García-Tirado, DTM 2022: RocketAP in Practice: Results from Pilot and Feasibility Trials

José García-Tirado, DTM 2022: Challenges in the development of artificial pancreas systems

Carol Levy, DTM 2022: The use of Control-IQ technology in prior MDI and basal-only insulin users with type 2 diabetes

Carol Levy, DTM 2022: Benefits of insulin pump in people living with type 2 diabetes

Latest articles videos and clinical updates - straight to your inbox

Connect With Us

Useful Links

In Partnership With

Specialities

Sign Up for Free Access to the Latest Clinical Updates in Your Specialty!

Learning Activities

Journals

Specialities

Trending Topic

Connect With Us:

IDF Congress 2019, Busan, Korea

This Content is forMembers Only

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Register now for FREE Access

Sign up with an Email

This Functionality is forMembers Only

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

This Content is for
Members Only

This Functionality is for
Members Only